NVO is trading 3.1% up now at $50.30 after Medicare officially launched its GLP-1 Bridge program for obesity drug Wegovy, expanding coverage with a $50 monthly copay for eligible beneficiaries. Investors are reacting to the improved U.S. reimbursement outlook for GLP-1 weight-loss treatments, which directly benefits Novo Nordisk’s Wegovy franchise and supports higher adoption and revenue expectations.